Do analysts recommend BCLI or SNYR?

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 2,919.32%. Given Synergy CHC's higher possible upside, analysts plainly believe Synergy CHC is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BCLI or SNYR more profitable?

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Synergy CHC -60.02% N/A -30.30%

Does the media refer more to BCLI or SNYR?

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 1 articles in the media. Synergy CHC's average media sentiment score of 0.84 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Synergy CHC 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SNYR or FNCH?

Synergy CHC currently has a consensus target price of $6.25, indicating a potential upside of 2,919.32%. Given Synergy CHC's stronger consensus rating and higher possible upside, research analysts plainly believe Synergy CHC is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer SNYR or PHXM?

Synergy CHC presently has a consensus price target of $6.25, suggesting a potential upside of 2,919.32%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, SNYR or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Synergy CHC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synergy CHC $27.70M 0.11 -$12.34M -$1.40 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is SNYR or PHXM more profitable?

PHAXIAM Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Company Net Margins Return on Equity Return on Assets Synergy CHC -60.02% N/A -30.30% PHAXIAM Therapeutics N/A N/A N/A

Synergy CHC (SNYR) Competitors

$0.21 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

SNYR vs. BCLI, KPRX, PHIO, FNCH, and PHXM

Should you buy Synergy CHC stock or one of its competitors? MarketBeat compares Synergy CHC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synergy CHC include Brainstorm Cell Therapeutics (BCLI), Kiora Pharmaceuticals (KPRX), Phio Pharmaceuticals (PHIO), Finch Therapeutics Group (FNCH), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.

How does Synergy CHC compare to Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Synergy CHC	-60.02%	N/A	-30.30%

Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 32.9% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Synergy CHC. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Synergy CHC	$27.70M	0.11	-$12.34M	-$1.40	N/A

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 2,919.32%. Given Synergy CHC's higher possible upside, analysts plainly believe Synergy CHC is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 1 articles in the media. Synergy CHC's average media sentiment score of 0.84 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synergy CHC	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Synergy CHC beats Brainstorm Cell Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Synergy CHC compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Kiora Pharmaceuticals has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Synergy CHC	-60.02%	N/A	-30.30%

Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market.

Kiora Pharmaceuticals has higher earnings, but lower revenue than Synergy CHC. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A
Synergy CHC	$27.70M	0.11	-$12.34M	-$1.40	N/A

In the previous week, Synergy CHC had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Synergy CHC and 0 mentions for Kiora Pharmaceuticals. Synergy CHC's average media sentiment score of 0.84 beat Kiora Pharmaceuticals' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Synergy CHC	Positive

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 32.9% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 280.23%. Synergy CHC has a consensus price target of $6.25, indicating a potential upside of 2,919.32%. Given Synergy CHC's higher possible upside, analysts clearly believe Synergy CHC is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Synergy CHC beats Kiora Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Synergy CHC compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Phio Pharmaceuticals currently has a consensus price target of $14.00, indicating a potential upside of 1,300.00%. Synergy CHC has a consensus price target of $6.25, indicating a potential upside of 2,919.32%. Given Synergy CHC's higher probable upside, analysts clearly believe Synergy CHC is more favorable than Phio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market.

In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 1 articles in the media. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Synergy CHC's score of 0.84 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
Synergy CHC	Positive

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 32.9% of Synergy CHC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Phio Pharmaceuticals has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Synergy CHC	-60.02%	N/A	-30.30%

Phio Pharmaceuticals has higher earnings, but lower revenue than Synergy CHC. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Synergy CHC	$27.70M	0.11	-$12.34M	-$1.40	N/A

Summary

Synergy CHC beats Phio Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Synergy CHC compare to Finch Therapeutics Group?

Synergy CHC (NASDAQ:SNYR) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Synergy CHC currently has a consensus target price of $6.25, indicating a potential upside of 2,919.32%. Given Synergy CHC's stronger consensus rating and higher possible upside, research analysts plainly believe Synergy CHC is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Synergy CHC has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Finch Therapeutics Group has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

21.8% of Finch Therapeutics Group shares are owned by institutional investors. 32.9% of Synergy CHC shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Synergy CHC had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Synergy CHC and 0 mentions for Finch Therapeutics Group. Synergy CHC's average media sentiment score of 0.84 beat Finch Therapeutics Group's score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media.

Company	Overall Sentiment
Synergy CHC	Positive
Finch Therapeutics Group	Neutral

Synergy CHC has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$27.70M	0.11	-$12.34M	-$1.40	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Summary

Synergy CHC beats Finch Therapeutics Group on 10 of the 15 factors compared between the two stocks.

How does Synergy CHC compare to PHAXIAM Therapeutics?

Synergy CHC (NASDAQ:SNYR) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

PHAXIAM Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
PHAXIAM Therapeutics	N/A	N/A	N/A

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 32.9% of Synergy CHC shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Synergy CHC has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

In the previous week, Synergy CHC had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Synergy CHC and 0 mentions for PHAXIAM Therapeutics. Synergy CHC's average media sentiment score of 0.84 beat PHAXIAM Therapeutics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media.

Company	Overall Sentiment
Synergy CHC	Positive
PHAXIAM Therapeutics	Neutral

Synergy CHC presently has a consensus price target of $6.25, suggesting a potential upside of 2,919.32%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PHAXIAM Therapeutics has lower revenue, but higher earnings than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$27.70M	0.11	-$12.34M	-$1.40	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

Synergy CHC beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Synergy CHC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNYR vs. The Competition

Export

Metric	Synergy CHC	CONS PD Industry	Staples Sector	NASDAQ Exchange
Market Cap	$3.12M	$31.23B	$16.76B	$12.48B
Dividend Yield	N/A	3.20%	3.29%	6.52%
P/E Ratio	-0.15	79.21	26.95	24.70
Price / Sales	0.11	1.67	47.25	99.42
Price / Cash	N/A	33.26	16.87	57.09
Price / Book	-0.10	11.54	5.66	6.46
Net Income	-$12.34M	$1.30B	$680.96M	$337.01M
7 Day Performance	-1.05%	4.70%	1.00%	1.69%
1 Month Performance	-0.77%	19.55%	4.35%	3.81%
1 Year Performance	-93.61%	-12.87%	-13.00%	23.90%

Synergy CHC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNYR Synergy CHC	3.493 of 5 stars	$0.21 flat	$6.25 +2,919.3%	-93.6%	$3.12M	$27.70M	N/A	40
BCLI Brainstorm Cell Therapeutics	0.2667 of 5 stars	$1.09 +9.0%	N/A	+26.3%	$12.03M	N/A	N/A	40	News Coverage Gap Down
KPRX Kiora Pharmaceuticals	1.9389 of 5 stars	$2.68 +1.9%	$10.00 +273.1%	-8.2%	$11.87M	$16.02M	N/A	10	News Coverage
PHIO Phio Pharmaceuticals	4.1636 of 5 stars	$1.02 -0.5%	$14.00 +1,272.5%	-58.9%	$11.85M	N/A	N/A	10	Positive News
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNYR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synergy CHC (SNYR) Competitors

SNYR vs. BCLI, KPRX, PHIO, FNCH, and PHXM

How does Synergy CHC compare to Brainstorm Cell Therapeutics?

Summary

How does Synergy CHC compare to Kiora Pharmaceuticals?

Summary

How does Synergy CHC compare to Phio Pharmaceuticals?

Summary

How does Synergy CHC compare to Finch Therapeutics Group?

Summary

How does Synergy CHC compare to PHAXIAM Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synergy CHC (SNYR) Competitors

SNYR vs. BCLI, KPRX, PHIO, FNCH, and PHXM

How does Synergy CHC compare to Brainstorm Cell Therapeutics?

Is BCLI or SNYR more profitable?

Which has more risk and volatility, BCLI or SNYR?

Do institutionals and insiders believe in BCLI or SNYR?

Which has preferable earnings and valuation, BCLI or SNYR?

Do analysts recommend BCLI or SNYR?

Does the media refer more to BCLI or SNYR?

Summary

How does Synergy CHC compare to Kiora Pharmaceuticals?

Is KPRX or SNYR more profitable?

Which has more volatility & risk, KPRX or SNYR?

Which has preferable valuation & earnings, KPRX or SNYR?

Does the media favor KPRX or SNYR?

Do insiders & institutionals have more ownership in KPRX or SNYR?

Do analysts recommend KPRX or SNYR?

Summary

How does Synergy CHC compare to Phio Pharmaceuticals?

Do analysts rate PHIO or SNYR?

Which has more volatility & risk, PHIO or SNYR?

Does the media refer more to PHIO or SNYR?

Do institutionals & insiders have more ownership in PHIO or SNYR?

Is PHIO or SNYR more profitable?

Which has higher earnings and valuation, PHIO or SNYR?

Summary

How does Synergy CHC compare to Finch Therapeutics Group?

Do analysts rate SNYR or FNCH?

Which has more volatility and risk, SNYR or FNCH?

Is SNYR or FNCH more profitable?

Do insiders & institutionals have more ownership in SNYR or FNCH?

Does the media refer more to SNYR or FNCH?

Which has preferable valuation and earnings, SNYR or FNCH?

Summary

How does Synergy CHC compare to PHAXIAM Therapeutics?

Is SNYR or PHXM more profitable?

Do insiders and institutionals hold more shares of SNYR or PHXM?

Which has more risk and volatility, SNYR or PHXM?

Does the media prefer SNYR or PHXM?

Do analysts prefer SNYR or PHXM?

Which has better earnings and valuation, SNYR or PHXM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools